London’s AIM All Share advanced on Monday in line with most global markets. The index closed up 11 at 658.89.
- Scancell +38%
- Wishbone +24%
- Distil +18%
- Pantheon -41%
- Nahl -12%
Scancell LON:SCLP was the biggest riser, up 38% following news that the company had agreed a deal with the NHS in terms of trials for its skin cancer therapy. Data from the study will be used to implement the development plan towards registration in 2026.
Wishbone Group LON:WSBN finished the day 24% higher. There’s no news here but the company does seem to be enjoying the halo effect of the ongoing increase in gold prices.
- AIM Market Roundup: Empyrean Energy, Tern, Thruvision
- AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics
Distil LON:DIS gets the notable mention, up 18% following news this morning that the company had agreed a partnership for US distribution of its spirits. This will bring Blavod Black Vodka back into the market, where it was sold pre-pandemic. AIKO, a nationally recognised importer will be facilitating.
Pantheon LON:PANR was 41% lower following test results which failed to produce the expected readings at some intervals. Management are keen to stress that this data could indicate the presence of more productive shallower depths, but the market wasn’t buying it.
Nahl Group LON:NAH was 12% lower, but there’s no news here and what trade we did see was fairly limp.
